GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.

Target
Company Name
Target
Country
Description

GrandPharm obtained the right to develop and commercialize BRM421 in greater China. At the same time, GrandPharm subscribed for a small amount of equity of Brimbiotech

Global M&A Offices
Hollyhigh International Capital (Global M&A China)
Global M&A Advisory Advisor to the seller
Further information

For further details, see: https://www.brimbiotech.com/en...

and http://www.grandpharma.cn/en/A...